Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Impact of baseline SARS-CoV-2 antibody status on syndromic surveillance and the risk of subsequent COVID-19—a prospective multicenter cohort study

Fig. 3

Frequency of symptoms during a median follow-up of 7.9 months based on 101,233 weekly diaries from participants with (n = 144) and without (n = 4668) specific SARS-CoV-2 antibodies at baseline. Symptoms are sorted by increasing risk ratio. Error bars show 95% Wilson confidence intervals. P values calculated by two-sample proportion test

Back to article page